ProfileGDS5678 / 1455333_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 93% 93% 93% 96% 92% 95% 96% 94% 95% 93% 93% 93% 94% 93% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.931193
GSM967853U87-EV human glioblastoma xenograft - Control 28.0326193
GSM967854U87-EV human glioblastoma xenograft - Control 37.8618693
GSM967855U87-EV human glioblastoma xenograft - Control 48.8277696
GSM967856U87-EV human glioblastoma xenograft - Control 57.8129392
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 18.0852295
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 28.4704596
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 38.2045694
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 48.3011395
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.8629493
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.915893
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 38.0308693
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 48.0244294
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.9128993